Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00959036 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating Multiple Doses Of ATN-103 In Subjects With Active Rheumatoid Arthritis
A Phase 1 study of Active Rheumatoid Arthritis, sponsored by Ablynx, a Sanofi company.
- Completed
- Registry status
- Phase 1
- Development phase
- 252
- Enrollment target
- 20
- Study locations
NCT00959036 is a Phase 1 study of Active Rheumatoid Arthritis that has completed, run by Ablynx, a Sanofi company. The registered enrollment target is 252 participants. The trial reports 20 study locations across 13 states.
The verdict
NCT00959036, a Phase 1 study of Active Rheumatoid Arthritis, has completed, sponsored by Ablynx, a Sanofi company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 252 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and efficacy of ATN-103 when administered to subjects with active rheumatoid arthritis compared with placebo. All subjects must be on a stable dose and route of methotrexate.
Conditions Studied
Interventions
- DRUG ATN-103
Study Locations (20)
Florida
- Investigational Site - Lake Mary
- Investigational Site - Ocala
- Investigational Site - Orlando
- Investigational Site - Port Orange
- Investigational Site - Vero Beach
Alabama
- Investigational Site - Birmingham
- Investigational Site - Huntsville
Arizona
- Investigational Site - Peoria
- Investigational Site - Scottsdale
California
- Investigational Site - Riverside
- Investigational Site - Upland
Connecticut
- Investigational Site - Bridgeport
Delaware
- Investigational Site - Newark
Idaho
- Investigational Site - Coeur d'Alene
Maryland
- Investigational Site - Frederick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 252 participants |
| Start Date | 2009-09 |
| Est. Completion | 2011-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00959036
The ClinicalTrials.gov registry entry for NCT00959036 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 252 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ablynx, a Sanofi company, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Active Rheumatoid Arthritis appearing as the primary indexed condition, and to 1 intervention - of which ATN-103 is the first listed.
NCT00959036 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Florida, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT00959036 about?
NCT00959036 is a clinical study titled "Study Evaluating Multiple Doses Of ATN-103 In Subjects With Active Rheumatoid Arthritis". The purpose of this study is to evaluate the safety and efficacy of ATN-103 when administered to subjects with active rheumatoid arthritis compared with placebo. All subjects must be on a stable dose and route of methotrexate.
What is the current status of trial NCT00959036?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 252 participants. The study started on 2009-09. Estimated completion is 2011-01.
What conditions does trial NCT00959036 study?
This clinical trial studies the following conditions: Active Rheumatoid Arthritis.
What interventions are being tested in trial NCT00959036?
The interventions under investigation include: ATN-103 (DRUG).
Who is sponsoring clinical trial NCT00959036?
This trial is sponsored by Ablynx, a Sanofi company, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00959036 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.